Ceftolozane/Tazobactam

제한된
1
C. difficile 위험도
High
경구생체이용률
N/A

Dosing

Complicated UTI (including pyelonephritis)Complicated intraabdominal infection in combination with MetronidazoleHAP/VAP1.5 g (Ceftolozane 1 g/Tazobactam 0.5 g) IV infused over 1h q8h x7d1.5 g IV q8h x4-14d + Metronidazole 500 mg IV q8h3 g (Ceftolozane 2 g/Tazobactam 1 g) IV infused over 1h q8h x8-14d

Safety and efficacy in pediatric patients have not been established

No dose adjustment

CrCl 30-50CrCl 15-29CrCl <15, HD- IAI, UTI: 750 mg IV q8h

  • HAP/VAP: 1.5 g IV q8h- IAI, UTI: 375 mg IV q8h

  • HAP/VAP: 750 mg IV q8h- IAI, UTI: 750 mg IV load, then 150 mg IV q8h (dose after HD on HD days)

  • HAP/VAP: 2.25 g IV load, then 450 mg IV q8h (dose after HD on HD days)

General Information

  • In patients with documented multi-drug resistant (MDR) Pseudomonas or CRE organisms

  • Complicated urinary tract infection

  • Hospital acquired pneumonia

  • Ventilator-associated pneumonia

  • Infectious disease of abdomen, Complicated disease, in combination with metronidazole

  • Pyelonephritis

Improvement in signs and symptoms of infection are indicative of efficacy.

Monitor patients with changing renal function; CrCl at least daily.

Consider monitoring renal function on elderly patients.

Common

  • Fever

  • Headache

  • Diarrhea

  • Nausea

Serious

  • Clostridium difficile colitis

  • Clostridium difficile diarrhea

  • Hypersensitivity reaction

  • Intracranial hemorrhage

  • Renal impairment

  • Cholera vaccine - reduced immune response to the cholera vaccine

  • Probenecid - increased risk of elevated tazobactam serum concentrations

Antimicrobial Class: Cephalosporin, Penicillinase inhibitor

Pregnancy Category: B

Average serum half life: 1.9-4 hours (Ceftolozane), 0.7-3 hours (Tazobactam)

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Precautions:

  • Increased risk of adverse effects in patients with moderate or severe renal impairment and those with ESRD on hemodialysis; monitoring recommended and dose adjustments required.

  • Decreased efficacy has been reported in patients with baseline creatinine clearance of 30-50 mL/min; monitoring recommended.

  • Infectious Diseases consult required for use (intensivists can order empirically in the ICU, if known MDR organism until ID can be consulted).

  • Should be reserved for patients with little or no other treatment alternatives.

Attribution: Antimicrobial information adapted from Sault Area Hospital

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.